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Abstract
Background Cognitive functioning has been linked to employment outcomes in multiple sclerosis (MS) in cross-sectional
studies. Longitudinal studies are however lacking and previous studies did not extensively examine executive functioning.
Objectives We examined whether baseline cognitive functioning predicts a change in employment status after 2 years, while
taking into account mood, fatigue and disability level.
Methods A total of 124 patients with relapsing-remitting MS (pwMS) and 60 healthy controls were included. They underwent
neurological and neuropsychological examinations and completed online questionnaires. PwMS were divided into a stable and
deteriorated employment status group (SES and DES), based on employment status 2 years after baseline. We first examined
baseline differences between the SES and DES groups in cognitive functioning, mood, fatigue and disability level. A logistic
regression analysis was performed, with change in employment status (SES/DES) as dependent variable.
Results The DES group included 22% pwMS. Group differences were found in complex attention, executive functioning, self-
reported cognitive functioning, fatigue and physical disability. More physical disability (OR = 1.90, p = 0.01) and lower execu-
tive functioning (OR = 0.30, p = 0.03) were retained as independent predictors of DES (R2 = 0.22, p ≤ 0.001).
Conclusions Baseline physical disability and executive functioning, but none of the other variables, moderately predicted a
deterioration in employment status 2 years later.
Trial registration This observational study is registered under NL43098.008.12: ‘Voorspellers van arbeidsparticipatie bij mensen
met relapsing-remitting Multiple Sclerose’. This study is registered at the Dutch CCMO register (https://www.toetsingonline.nl).
Keywords Multiple sclerosis .Work . Employment . Cognition . Executive function . Physically disabled
Introduction
Work participation plays an important role in our lives and is
often linked to quality of life. Besides income, work partici-
pation is known to promote a person’s sense of self-respect
and social contacts and provides a feeling of usefulness and
satisfaction [1]. Living with a chronic illness can make it
challenging to meet the demands of working life. As a result,
work participation is often compromised in patients with mul-
tiple sclerosis (pwMS) with unemployment rates up to 80%
[2]. In those who remain in the workforce, a reduction in hours
or work responsibilities, presenteeism and increased time
missed from work is often observed [3].
Whether and how pwMS participate in work depends on
multiple factors [4, 5]. Physical disability, disease duration, the
patient’s age, fatigue, walking problems, cognitive and neuro-
psychological impairments are linked to difficulties with work
participation [4, 6]. Cognitive impairment is present in an esti-
mated 43 to 65% of pwMS and can be present at all stages of the
disease [7]. In accordance with the fickle nature of the disease, a
wide variety of cognitive deficits can be observed in MS with a
great inter-patient variability. In addition, cognitive resources
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have become more important as the work field over the past
decades has changed from an industrial to a post-industrial set-
ting, resulting into a shift from more physically challenging
work toward more mentally challenging work [8]. Studies have
suggested that cognitive functioning, either self-reported or ob-
jectively assessed with a cognitive examination, plays an impor-
tant role in work participation. Specifically, self-reported cogni-
tive difficulties, global cognitive impairment and lower scores
on processing speed/working memory, executive functioning
and memory have been linked to worse work outcomes in MS
[9–11]. The majority of studies on cognitive functioning and
work outcomes are, however, cross-sectional, which makes it
impossible to draw conclusions about causality of relationships,
and on the predictive value of cognitive functioning regarding
work participation inMS. The few longitudinal studies that were
conducted found evidence for the predictive value of processing
speed/working memory for future employment status [12–14].
Many of the previous studies, including the longitudinal ones,
did not examine executive functioning in much detail, while
measures of conceptual reasoning, switching and inhibition
may be important associates of work functioning [13, 15].
In the current study, we aim to investigate whether baseline
cognitive functioning predicts a change in employment status




For this study, pwMS from 16 MS outpatient clinics in the
Netherlands were recruited in the context of the MS@Work
study, a prospective longitudinal study on work participation
in patients with relapsing-remitting MS [5]. The criteria for
inclusion were a diagnosis of relapsing-remitting MS [16], pa-
tients had to be 18 years and older and currently employed or
within 3 years since their last employment. Patients with co-
morbid psychiatric or neurological disorders, substance abuse,
neurological impairment that might interfere with cognitive
testing, or inability to speak and/or read Dutch were excluded
from the study. A healthy control group was recruited through
advertisements on social media and in local newspapers. For
the healthy control group, the same inclusion and exclusion
criteria were used, except for absence of a chronic disorder.
PwMS underwent neurological and neuropsychological
examinations at their outpatient clinics and were asked to fill
in online questionnaires yearly for a period of 3 years. The
healthy controls underwent a neuropsychological examination
at baseline and were asked to fill in the online questionnaires
yearly for a period of 3 years. For this study, the baseline and
2-year data were used. The online questionnaires assessed
demographic characteristics, work participation, empathy,
self-reported cognitive and neuropsychiatric functioning, fa-
tigue and mood.
The MS@Work study was approved by the Medical
Ethical Committee Brabant (NL43098.008.12 1307; date of
approval: 12-02-2014) and the Board of Directors of the par-
ticipating MS outpatient clinics. All subjects provided written
informed consent. The study was performed in agreement
with the Declaration of Helsinki [17].
Participants
The current study included pwMS who were employed at
baseline, completed the baseline assessments and completed
questionnaires about their work situation after 2 years (see
Fig. 1 for a flow chart of the inclusion of participants).
Participants were categorised into a stable employment status
(SES) group (n = 97) and a deteriorated employment status
(DES) group (n = 27), based on deteriorations in their work
status after 2 years (see measures for a definition). We includ-
ed 60 healthy controls, matched for age, sex and education to
be able to calculate Z-scores for cognitive functioning, anxi-
ety, depression and fatigue.
Measures
Neuropsychological examination
The neuropsychological examination included various neuro-
psychological tests assessing the neurocognitive domains as
described in the Diagnostic and Statistical Manual of Mental
Disorders-V [18] (i.e. complex attention, learning and memo-
ry, language, executive functioning, perceptual motor func-
tioning and social cognition). For an overview of the neuro-
psychological tests and measures, see Table 1. Most tests are
part of the Minimal Assessment of Cognitive Function in MS
battery [19]. The Multiple Sclerosis Neuropsychological
Screening Questionnaire [20] was used to examine self-
reported cognitive and neuropsychiatric functioning.
Neuropsychological test scores were transformed into Z-
scores based on the healthy control group and composite Z-
scores were calculated per neurocognitive domain.
Employment status
A general questionnaire was used to inquire about demo-
graphic characteristics and work participation in both the pa-
tients and healthy controls. The general questionnaire was
administered at baseline and 2 years after baseline.
Participants were regarded to be employed if they were in a
paid job or reported to be self-employed. Students, volunteer
workers and participants who had reached the retirement age
were excluded from analysis.
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Participants were divided into SES and DES groups
based on deteriorations reported in the 2-year data. A
participant was considered to be part of the DES group
if they either had stopped working due to MS or had
Table 1 Neuropsychological tests and measures used per Diagnostic and Statistical Manual of Mental Disorders-V neurocognitive domain
Neuropsychological test Measure
Complex attention Symbol Digit Modalities Test
Trail Making Test
Colour Word Interference Testa
Total correct
Completion time part A
Completion time colour naming
Completion time reading
Learning and memory Rey Verbal Learning Test
Brief Visuospatial Memory Test-Revised
Total correct immediate recall
Total correct delayed recall
Total correct immediate recall
Total correct delayed recall
Language Controlled Oral Word Association Test
Semantic Category Fluency Test
Total correct
Total correct
Executive functioning Paced Auditory Serial Addition Test
Trail Making test
Colour Word Interference Testa
Design Fluency Testa
Total correct on both 3′ and 2′
Completion time part B
Contrast score (part B – part A)
Completion time inhibition
Completion time inhibition/switching
Contrast score (inhibition – colour naming
Contrast score (inhibition/switching – combined colour
naming and word reading)
Total correct 3 conditions
Contrast score (switching – combined full dots and empty dots)
Perceptual motor functioning Judgement of Line Orientation Test Total correct
Social cognition Empathy Quotientb Total score
a Delis Kaplan Executive Functioning Systems subtest. b Questionnaire. For a detailed description of the neuropsychological tests and measures, we refer
to MS@Work study protocol [5]
Paents that completed the 
2-year assessment (N = 148)
Excluded:
- baseline quesonnaires and/or        
cognive test scores not available (N = 5)
- not employed at baseline (N = 16)
Total paents included 
(N = 127)
Deteriorated employment group (N = 27)
- stopped working aer 2 years (N = 9)
- reduced work hours 70% (N = 4)
- reduced work hours 50 % (N = 7)
- reduced work hours 20% (N = 7)
Stable employment group (n = 97)
- no reported diﬀerences (N = 93)
- increase in work hours (N = 4)
Excluded: stopped or reduced work hours aer 
two years for reasons other than MS;
- parental leave (N = 1)
- reorganizaon in the company (N = 1)
- rerement age (N = 1)
Total paents included in 
analysis
(N = 124)
Fig. 1 Flow chart of the inclusion
of patients with MS
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decreased their work hours due to MS by at least 20%
based on self-reports. Participants, who reported no dif-
ferences or had increased their work hours, were includ-
ed in the SES group.
Other clinical measures
The Expanded Disability Status Scale (EDSS) was used to
examine physical disability in pwMS [21] and was adminis-
tered by a neurologist in the outpatient clinic where the pa-
tients were being treated. Scores range from 0 (normal neuro-
logical exam) to 10 (death due to MS) and increment with
steps of 0.5. Scores between 0 and 3.5 represent mild disabil-
ity, scores between 4.0 and 6.5 represent moderate disability
and scores of 7.0 and above represent severe disability [22].
The Hospital Anxiety and Depression Scale [23] was used to
examine self-reported symptoms of anxiety and depression.
The Modified Fatigue Impact Scale was used to measure the
self-reported impact of fatigue on daily functioning [24].
Statistical analysis
IBM SPSS for Windows (release 23.0) was used for data
analysis. Z-scores were calculated for the neurocognitive mea-
sures, self-reported cognitive functioning, depression, anxiety
and fatigue based on the mean and standard deviation (SD)
from the healthy control group. Z-scores were scaled in such a
way that lower scores represent worse functioning and com-
bined into a mean Z-score for each neurocognitive domain.
In the first step of analysis, we investigated differences
between the SES and DES groups in Z-scores per
neurocognitive domain and other clinical measures using
parametric or non-parametric tests where appropriate.
In the second step of analysis, we conducted a logistic
regression analysis, with change in employment status (SES/
DES) as dependent variable. As potential predictors, we in-
cluded the Z-scores per neurocognitive domain and the other
clinical measures that significantly differed between the DES
and SES group as shown in the previous step of the analysis.
The level of statistical significance was set at p ≤ 0.05.
Results
Characteristics of patients with MS
Demographics and disease characteristics of the pwMS and
healthy controls are presented in Table 2. Patients and healthy
controls did not differ significantly in gender, age, educational
level and type of job. The pwMS worked significantly less
hours than the healthy controls (U = 2246.0, p < 0.001). Most
pwMS had a white collar job (88.2%), with the majority being
employed in office and administrative support (20.5%), the
healthcare sector (16.5%) or education sector (11.8%). The
pwMS were characterised by mild disability (median 2.0).
In Table 3, the mean Z-scores for the neurocognitive do-
mains, self-reported cognitive functioning, anxiety, depres-
sion and fatigue are presented. The neurocognitive domains
where patients most frequently scored below average (≤ 2SD
as compared with healthy controls) are complex attention
(8.9%), followed by perceptual motor functioning (5.7%)
and learning and memory (3.2%). A total of 20 pwMS
(16.1%) scored below average (≤ 2SD) on at least one
neurocognitive domain. A total of 8.9% and 10.5% of the
pwMS reported scores indicative of major depression and
generalised anxiety, and 26.6% reported scores indicative of
MS-related fatigue (based on ≤ 2SD).
Baseline comparisons between the SES and DES
groups
Baseline comparisons between the SES and DES groups in de-
mographic characteristics, cognitive functioning and clinical
characteristics are presented in Table 4. In 27 cases, patient’s
employment deteriorated (DES; 22%). Of the 97 that were in
the SES group (78%), four patients reported an increase in work
hours. The SES and DES groups did not differ in gender, age,
educational level, work hours, type of work, the use of immuno-
modulatory treatment, disease duration, learning and memory,
language, perceptual-motor functioning, social cognition and
anxiety at baseline. The DES group showed more physical dis-
ability, lower complex attention and executive functioning, more
self-reported cognitive problems, more symptoms of depression,
and more fatigue than the SES group at baseline.
Predictors of changes in employment status
after 2 years
Results of the logistic regression analysis are presented in
Table 5. Lower executive functioning and more physical disabil-
ity were retained as independent predictors of DES. All other
variables did not independently contribute to the prediction.
Discussion
This longitudinal study shows that pwMS who deteriorated in
employment status after 2 years due to MS showed lower
executive functioning, more self-reported cognitive problems,
more symptoms of depression, higher fatigue and higher
physical disability (i.e. higher EDSS scores) at baseline.
These findings are in accordance with factors that have previ-
ously been linked to worse employment outcomes in cross-
sectional studies [6]. Our logistic regression model retained
more physical disability and lower executive functioning as
independent baseline predictors of a deterioration in
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employment status over a 2-year period. All other variables
did not significantly predict DES 2 years after baseline. Both
physical disability and executive functioning have previously
been linked with work participation in multiple (mostly)
cross-sectional studies [6, 9]. Although the level of physical
disability in our group of pwMS can be considered mild, it
seems that more physical disability is an important risk factor
for less favourable employment outcomes over time.
None of the pwMS in this study showed below average (<
2SD) executive functioning at baseline. Still, lower executive
functioning was found to be predictive of DES. This is not sur-
prising, because executive functioning is thought to be crucial for
successful work participation, as most job demands include ex-
ecutive abilities such as problem solving, planning and reasoning
[25].
Comparing our results with the few other longitudinal stud-
ies, Morrow et al. (2010) found that both baseline and a de-
cline in processing speed/working memory (Symbol Digit
Modalities Test) and verbal memory predicted a deterioration
in vocational status 3 years later [12]. Ruet et al. (2013) found
that lower baseline processing speed/working memory
(Symbol Digit Modalities Test and Paced Auditory Serial
Addition Test), more physical disability and higher age were
significantly associated with a decreased employment status
after 7 years [13]. In the register-based cohort study by
Kavaliunas et al. (2019), a relation between baseline lower
processing speed (Symbol Digit Modalities Test) and work
disability (sickness absence and disability pensioned) at 1
and 3 years after follow-up was found [14].
Table 2 Baseline demographic and disease characteristics of the patients with MS and the healthy control group
Patients with MS Healthy control group
N % Mean (SD) Median (IQR) Min–max N % Mean (SD) Median (IQR) Min-max
Gender (% female) 124 82.3% 60 80%
Age 124 42.3 (9.0) 43.0 (13.0) 21–63 60 41.9 (10.3) 44.0 (15.0) 20–64
Educational level 124 60
Low 21 16.9% 3 5.0%
Medium 47 37.9% 27 45.0%
High 56 45.2% 30 50.0%
Number of work hours per week 124 26.2 (11.0) 24.0 (18.0) 3–55 60 33.4 (8.3) 36.0 (12.0) 12–50
Type of work (%white collar) 124 87.9% 60 81.7%




Disease duration (in years) 124 7.6 (6.2) 6.0 (7.8) 0–28 n.a.
Education was divided into three levels: low education (up to finishing low-level secondary school), middle education (finishing secondary school at a
medium level) or high education (finished secondary school at the highest level and/or obtained a college or university degree). a Neurological data was
not available for 9 patients with MS; n.a., not applicable
Table 3 Z-scores for each DMS-V neurocognitive domain, self-reported cognitive functioning, anxiety, depression and fatigue for patients with MS
N Mean
Z-score
Min–max N with Z-score
≤ − 2
% with Z-scores ≤ − 2
Complex attention 124 − 0.37 − 4.68–2.12 11 8.9%
Learning and memory 124 − 0.31 − 3.71–1.38 4 3.2%
Language 124 − 0.52 − 2.24–2.40 3 2.4%
Executive functioning 119a − 0.04 − 1.38–1.47 0 0.0%
Perceptual motor functioning 123b − 0.24 − 4.17–1.00 7 5.7%
Social cognition 124 − 0.11 − 2.72–1.93 2 1.6%
Self-reported cognitive functioning 124 − 0.44 − 4.77–2.37 14 11.3%
Self-reported anxiety 124 − 0.55 − 4.72–1.61 13 10.5%
Self-reported depression 124 − 0.63 − 5.61–0.65 11 8.9%
Self-reported fatigue 124 − 1.16 − 4.29–1.54 33 26.6%
aData not complete due to technical issues (N = 3) or wrong administration (N = 2) of the PacedAuditory Serial Addition Test and Design Fluency. b Data
missing due to unknown reason
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All these longitudinal studies found evidence for the influence
of processing speed/workingmemory on future employment sta-
tus, but did not comprehensively evaluate executive functioning.
In our study, the neurocognitive domain of executive func-
tioning reflects the combined performance on the Paced
Auditory Serial Addition Test and complex conditions of the
Trail Making Test, Colour Word Interference Test and Design
Fluency. Upon further inspection, we found that specifically the
scores on the Paced Auditory Serial Addition Test and Colour
Word Interference Test differed between the SES and DES
Table 4 Baseline comparisons in demographic characteristics, cognitive functioning, anxiety, depression and fatigue between the stable and
deteriorated employment groups












Gender (% female) 97 80.4% 27 88.9% X2 = 1.0 p = 0.31
Age, mean (SD) 97 42.2 (9.2) 21–63 27 42.6 (8.6) 29–58 T = − 0.2 p = 0.84
Educational level 97 27 X2 = 1.0 p = 0.60
Low (%) 16 16.5% 5 18.5%
Medium (%) 39 40.2% 8 29.6%
High (%) 42 43.3% 14 51.9%
Number of work hours, median (IQR) 97 25.0 (17.5) 3–55 27 24.0 (20.0) 8–40 U = 1224.0 p = 0.60
Type of work (% white collar) 97 85.6% 27 96.3% X2 = 2.3 p = 0.13
Expanded Disability Status Scale, median (IQR) 91 2.0 (1.0) 0–6 24 3.0 (2.0) 0–6 U = 557.0 p < 0.001*
Disease duration (in years), median (IQR) 97 5.0 (8.5) 0–28 27 7.0 (7.0) 1–26 U = 1170.5 p = 0.40
Medication (% using immunomodulatory treatment) 97 79.4% 27 81.5% X2 = 0.1 p = 0.81
Cognitive functioning
Complex attention, median (IQR) 97 − 0.20 (1.05) − 4.68–2.12 27 − 0.53 (1.49) − 4.49–0.86 U = 989.0 p = 0.05*
Learning and memory, mean (SD) 97 − 0.29 (0.84) − 3.42–1.38 27 − 0.38 (1.15) − 3.71–1.04 T = 0.4 p = 0.67
Language, mean (SD) 97 − 0.48 (0.74) − 2.02–2.40 27 − 0.65 (0.86) − 2.24–1.37 T = 1.0 p = 0.33
Executive functioning, mean (SD) 92 0.05 (0.55) − 1.29–1.47 27 − 0.35 (0.55) − 1.38–0.71 T = 3.3 p = 0.001*
Perceptual motor functioning, median (IQR) 97 − 0.09 (1.09) − 3.63–1.00 26 − 0.50 (1.36) − 4.17–1.00 U = 1121.5 p = 0.39
Social cognition, mean (SD) 97 − 0.16 (0.81) − 2.72–1.93 27 0.05 (0.96) − 1.79–1.65 T = − 1.1 p = 0.26
Self-reported cognitive functioning, mean (SD) 97 − 0.29 (1.35) − 4.77–2.37 27 − 0.98 (1.20) − 3.20–1.52 T = 2.4 p = 0.02*
Other clinical measures
Self-reported anxiety, median (IQR) 97 − 0.37 (1.58) − 4.32–1.61 27 − 0.37 (1.58) − 4.72–1.21 U = 1260.5 p = 0.77
Self-reported depression, median (IQR) 97 − 0.19 (1.25) − 3.94–0.65 27 − 1.02 (2.09) − 5.61–0.65 U = 935.5 p = 0.02*
Self-reported fatigue, median (IQR) 97 − 1.18 (1.48) − 4.14–1.54 27 − 1.57 (1.71) − 4.29–0.60 U = 862.5 p = 0.007*
*p values of ≤ 0.05 are considered significant
Table 5 Logistic regression
model of stable or deteriorated
employment after 2 years
Included B S.E. OR [95% CI OR] p value
Constant − 3.70 0.78 p ≤ 0.001*
Complex attention − 0.14 0.27 0.87 [0.51–1.47] p = 0.60
Executive functioning − 1.20 0.55 0.30 [0.10–0.88] p = 0.03*
Self-reported cognitive functioning − 0.18 0.32 0.84 [0.45–1.57] p = 0.58
Self-reported depression 0.36 0.29 1.43 [0.81–2.51] p = 0.22
Self-reported fatigue − 0.58 0.38 0.56 [0.27–1.18] p = 0.13
Expanded Disability Status Scale 0.64 0.25 1.90 [1.16–3.10] p = 0.01*
Model: R2 = 0.22 (Cox & Snell), R2 = 0.33 (Nagelkerke), Χ2 (6) = 26.9 p ≤ 0.001. *p values of ≤ 0.05 are con-
sidered significant. The model included = 110 patients with MS due to missing data on physical disability and
executive functioning
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groups (see online supplementary material). The Paced Auditory
Serial Addition Test has been previously linked to employment
outcomes in pwMS [19, 26] and is regarded as one of the most
sensitive measures for employment outcomes, together with the
Symbol Digit Modalities Test [11–13, 27]. The Colour Word
Interference Test measures both inhibition and cognitive flexibil-
ity [28] and may also be influenced by a processing speed com-
ponent. In the little research that has used the Colour Word
Interference Test as a measure of executive functioning in com-
binationwith employment status, no associations were found [29,
30]. However, the Colour Word Interference Test may provide a
measure of inhibition and cognitive flexibility (either combined
with processing speed) that is representative of the ability to over-
come challenges faced by individuals with MS in the workplace.
Although we observed group differences in self-reported cog-
nitive functioning, fatigue and depression between the SES and
DES groups, these variables were not retained as independent
predictors of DES after 2 years. Self-reported cognitive function-
ing as measured with the Multiple Sclerosis Neuropsychological
Screening Questionnaire was previously found to be related with
employment status [31] and negative work events [32].
Furthermore, previous research shows strong evidence that both
fatigue and depression are associated with work outcomes [6]. A
possible explanation for the lack of baseline predictive power is
that these variables are subject to time-dependent changes. It is
known that depression as well as anxiety can change over time in
pwMS [33]. In line, it seems intuitive that fatigue scores fluctuate
over time influenced by primary and secondary mechanisms
(e.g. sleep disorder, depression, iatrogenic mechanisms) [34]. It
would be interesting to further investigate change scores of fa-
tigue, depression, anxiety and self-reported cognitive functioning
over time in relation to changes in employment outcomes.
Even though physical disability and executive functioning are
predictors of DES, together they were only able to explain a
small part of the variance in DES. Work participation in MS is
a multifactorial problem and cannot solely be explained by the
measured variables. It is known that personal- and work-related
factors are related to work participation. For example, the will-
ingness of companies to facilitate suitable adaptations like flexi-
ble work schedule or accommodations to the workload may be
as important [35]. To date, the amount of studies investigating
these (and other) personal- and work-related factors is limited
and it might be of great interest to investigate these factors more
extensively.
Strengths and limitations
Strengths of the current study include its longitudinal charac-
ter, the use of a matched control group and the use of a com-
prehensive neuropsychological assessment. The study sample
was characterised by working patients with relapsing-
remitting MS, mild physical disability and a low prevalence
of patients showing below average performance on the six
neurocognitive domains (0–8.9%), and thus its findings may
probably not be generalisable to the entire MS population.
Furthermore, with the use of questionnaires, our self-
reported work measure may be subject to a recall bias.
In our outcome measure, we did not include presenteeism
or qualitative deteriorations in employment, like loss of re-
sponsibilities or other changes of function due to MS.
PwMS that worked in a less skilled job for the same number
of work hours 2 years after baseline, were not considered to be
in the deteriorated group. In this regard, it is possible that
pwMS in the stable group did qualitatively deteriorate in em-
ployment status and thus, the effects found could possibly be
an underestimation of the true effect.
In the current study, we have taken into account various
influential factors like mood, fatigue and disability level.
Another possible influential factor, that we did not take into
account, is the use of immunomodulatory treatment and
switches in treatment over time. Most patients in our sample
use disease-modifying drugs, and some of these drugs have
been reported to affect cognitive [36] and work functioning
[37]. In future studies, it might be interesting to also take into
account the potential effects of (changes in) disease-modifying
drugs on cognitive functioning and work participation over
time. In future research, it would be relevant to investigate
changes in cognitive functioning in relation to work participa-
tion over time. The only two prospective, longitudinal studies
that used a cognitive test battery found that changes in employ-
ment status after 3 and 7 years were predicted by both baseline
cognitive performance and cognitive deterioration during those
years [12, 13]. In future research, the relation between work
participation and a possible decrease in cognitive functioning
and other clinical-, personal- and work-related factors over time
should be investigated. As data collection of the MS@Work
study is still ongoing, we plan to focus on this issue in the future.
Although we used a matched control group to calculate
standardised scores for the neurocognitive measures, it would
be interesting to use meaningful and work-specific reference
criteria, such as minimal cognitive ability required to success-
fully perform a certain work task. This is in line with the
model of workload (mental and physical task load) and work
capacity (ability to execute a task) [38]. Similar work-related
reference values have been established for a functional capac-
ity evaluation of physical functioning [39]. However, refer-
ences are currently unavailable for cognitive functioning in
relation to work, which limits meaningful interpretation of
neuropsychological functioning in terms of work capacity,
and imposes a relevant venue for future research.
Conclusion
The current study revealed that lower executive functioning
and more physical disability are moderately predictive of a
Neurol Sci
deterioration in employment status after 2 years due to MS.
Mood and fatigue were not retained as independent predictors
of a deterioration in employment status. We should keep in
mind that work participation in pwMS is a multifactorial prob-
lem. Besides disease-related factors, it might be of great inter-
est to investigate personal- and work-related factors more
extensively.
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